Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:3/31/2015)... LONDON , March 31, 2015 /PRNewswire/ ... drug discovery applications have driven the need ... far the automated segments are going to ... this research. This study provides the market ... profiling and key trends for the liquid ...
(Date:3/31/2015)... , Mar. 27, 2015 Research and Markets ... the "Intraoperative Imaging Market by Type (Intraoperative CT, ... report to their offering. The global ... CAGR of 3.5% from 2014 to 2019 ... to a number of forces that favor this market. ...
(Date:3/31/2015)... -- RnRMarketResearch.com adds "Pemphigus - Pipeline ... 68 pages with latest updates, data and information ... The report "Pemphigus - Pipeline Review, H1 2015" report provides ... Pemphigus , complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
Breaking Medicine Technology:Western European Liquid Handling Market 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4
(Date:3/31/2015)... March 31, 2015 QMedET Solutions, ... 2, bringing the industry’s most advanced speech recognition ... community. Physicians can now experience the full benefits ... source, offering value-added support services that ensure successful ... , “QMedET is proud to provide Dragon Medical ...
(Date:3/31/2015)... The Oliver Law Group P.C. has launched ... client requests after Zofran lawsuits were filed in Massachusetts ... failed to warn physicians and their patients about the ... “illegally and fraudently” promoted Zofran as a treatment to ... that use from the U.S. Food and Drug Administration. ...
(Date:3/31/2015)... 31, 2015 The status of more ... discussed during a Case Management Conference scheduled to be ... New York on April 21st. According to court documents, ... litigation established for Mirena lawsuits filed on behalf of ... other serious complications related to the birth control device. ...
(Date:3/31/2015)... IL (PRWEB) March 31, 2015 Rising ... athletes have forced researchers and surgeons to better analyze ... the tissues used for repair. A recent study ... utilized a systematic review of 1,016 young, very active ... autograft tissues. , “This is the first review ...
(Date:3/31/2015)... These two automakers will address an audience of 400+ ... a shift that has become apparent in the motor ... for the insurance carriers alone. With connected car tech. ... in store for them. , Beyond more ... to their own involvement in the insurance process and ...
Breaking Medicine News(10 mins):Health News:QMedET Solutions Announces Addition of Dragon® Medical Practice Edition 2 to its Roster of Products 2Health News:Zofran Lawsuit Information Page Launched In Response To Clients Request For Information On Potential For Zofran Birth Defects, The Olive Law Group 2Health News:Zofran Lawsuit Information Page Launched In Response To Clients Request For Information On Potential For Zofran Birth Defects, The Olive Law Group 3Health News:Mirena IUD Lawsuits Move Forward as Federal Court Readies to Convene Next Case Management Conference 2Health News:Mirena IUD Lawsuits Move Forward as Federal Court Readies to Convene Next Case Management Conference 3Health News:ACL Failure Risks Increased in Young Patients Using Allografts 2Health News:TU-Automotive: Fiat and Renault-Nissan at the Centre of a Motor Insurance Evolution 2
... Donate Life California Organ & Tissue Donor Registry Reaches 2 ... Million Registrations ... Less Likely to Register, SACRAMENTO, Calif., Oct. 9 More than ... the,state,s Donate Life California Organ & Tissue Donor Registry, doubling the,state,s number ...
... Oct. 9 House Republican Whip Roy,Blunt (Mo.) ... Whip,James Clyburn (D-S.C.) yesterday suggested on CNN that ... override the president,s veto of the,SCHIP bill:, ... will be,hard-pressed to override the president,s veto of ...
... BOSTON--Like a crossword-puzzle solver who uses the letters in ... Cancer Institute and an international group of collaborators have ... breast cancer to identify a gene linked to non-hereditary ... a study posted online by the journal Nature Genetics, ...
... Pantoliano,reveals a personal history of depression and his ... in a guest blog entry, http://www.nami.org/blog published ... Pantoliano,s entry comes during Mental Illness Awareness ... opening of his latest film, CANVAS, http://www.canvasthefilm.com ...
... drinking and helped to boost abstinence, study finds , , ... to treat epileptic seizures could be added to the ... their addiction, a new study suggests. , The drug ... alcoholics stay away from heavy drinking, the study authors ...
... study is needed, and the therapy is valuable , , ... receiving androgen-deprivation therapy, a common form of hormone treatment ... face a nearly threefold higher risk of dying from ... danger results from a drop in testosterone levels that ...
Cached Medicine News:Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 2Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 3Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 4Health News:'Network' approach identifies potential breast cancer susceptibility gene 2Health News:'Network' approach identifies potential breast cancer susceptibility gene 3Health News:'Network' approach identifies potential breast cancer susceptibility gene 4Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 3Health News:Hormone Therapy for Prostate Cancer Linked to Heart Risks 2Health News:Hormone Therapy for Prostate Cancer Linked to Heart Risks 3Health News:Hormone Therapy for Prostate Cancer Linked to Heart Risks 4
... Agarose with low electroendosmosis ... most DNA/RNA applications. If ... to be used as ... ligase and restriction endonucleases, ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... standard gelling temperature, high gel strength agarose ... bp. This Genetic Technology Grade™ (GTG) agarose ... DNA recovered from SeaKem GTG Agarose gels ... GTG Agarose is extensively performance tested to ...
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso...
Medicine Products: